Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Operating Expenses (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Operating Expenses for 6 consecutive years, with $8.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses rose 74.01% to $8.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $26.0 million, a 20.73% increase, with the full-year FY2024 number at $20.2 million, down 21.03% from a year prior.
  • Operating Expenses was $8.7 million for Q3 2025 at Vivos Therapeutics, up from $7.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $10.5 million in Q4 2021 to a low of $4.6 million in Q2 2024.
  • A 5-year average of $7.1 million and a median of $7.0 million in 2025 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 97.42% in 2021, then crashed 31.84% in 2023.
  • Vivos Therapeutics' Operating Expenses stood at $10.5 million in 2021, then dropped by 19.69% to $8.4 million in 2022, then decreased by 26.34% to $6.2 million in 2023, then fell by 21.2% to $4.9 million in 2024, then soared by 76.71% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Operating Expenses are $8.7 million (Q3 2025), $7.0 million (Q2 2025), and $5.4 million (Q1 2025).